Fund moves
4.5%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
LNAI · NASDAQ · Pharmaceutical Preparations
No longer listed: the shares stopped trading on Oct 30, 2026, usually after a takeover, a merger or a move off the exchange. The price and the charts stop there; the filings stay.
Lunai Bioworks (LNAI) · oqro.io/stocks/LNAI · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.1648−0.0713 (−30.20%)
Close of Oct 29, 2026, vs Oct 28 · end-of-day
No open-market purchase by an insider of Lunai Bioworks was filed in the last 90 days. The latest on record was on May 18, 2022.
Since 2018, Lunai Bioworks insiders reported 17 open-market purchases and 19 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2022.
No open-market sale by an insider of Lunai Bioworks (LNAI) was filed with the SEC in the last 90 days.
No trade in Lunai Bioworks (LNAI) was disclosed by a member of Congress in the last 12 months.
Lunai Bioworks's next results are expected on Feb 15, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−97.9% (−$7.52) from Oct 29, 2025 to Oct 29, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $7.68 on Oct 29, 2025 to $0.1648 on Oct 29, 2026 (−97.9%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Suite 906 Los Angeles, Ca.
Last 12 months
Not enough history
Market value
$830K
Short interest: 19K shares sold short (0.4% of shares outstanding), −83.4% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2026
$52K
Year ended Jun 30, 2026
Net income, fiscal 2026
−$3.56M
A loss for the year
Shares outstanding
5.03M
As of Oct 13, 2026
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Insider selling
Traded Jul 29, 2024 · filed 87 days laterNot reported under a pre-arranged trading plan
A major shareholder of Lunai Bioworks sold $1.4K of Lunai Bioworks shares. The filing does not indicate a pre-arranged trading plan.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$31K
Free cash flow, last 12 months
−$1.84M
This quarter −$1.84M
Net debt
—
Debt —, cash $1.71M, at Jun 30, 2026
Net income, last 12 months
−$3.56M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
Lunai Bioworks Inc. operates principally through two operating subsidiaries, Renovaro Biosciences and BioSymetrics; a third wholly owned subsidiary, Lunai Bioworks IP, Inc., holds the intellectual property acquired in the May 2026 Neurobridge acquisition, including the N2B intranasal drug delivery platform (see Note 12 to the Financial Statements). BioSymetrics refers to BioSymetrics Inc. and its wholly owned subsidiary BioSymetrics Corp., which were acquired on April 8, 2025. During the quarter ended September 30, 2025, GEDi Cube, B.V., acquired on February 13, 2024, filed for bankruptcy and ceased operations. Following the deconsolidation of GEDi Cube B.V., consolidated operations now consist of Renovaro Biosciences cell and gene therapy programs and BioSymetrics AI platform.
And 12 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Oct 13, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Oct 13, 2026, compared with the one filed Sep 29, 2025. Read the filing
Securities Class Action Litigation. On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the “Chow Action” and the latter, the Manici Action”) were filed by purported stockholders of the Company in the United States District Court for the Central District of California against the Company and certain of the Company’s current and former officers and directors.
Source: SEC EDGAR, Form 10-K filed Oct 13, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Nobody is above 5% on the latest filings: every recent filer has reported going below the line.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Insiders of Lunai Bioworks reported 17 open-market purchases and 19 sales since 2018; purchases in 3 different years, most recently 2022.
| Year | Bought | Sold |
|---|---|---|
| 2024 | — | $724K13×13 trades |
| 2022 | $2.03M2×2 trades | $2.11M5×5 trades |
| 2019 | $1.1M8×8 trades | — |
| 2018 | $761K7×7 trades | $1.6M1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last results
—
Next results, expected
Feb 15, 2027
Purchases after results
Not enough history
From Lunai Bioworks's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Lunai Bioworks's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Off-exchange trading: 59.5% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (4.6% on ATS, 54.9% with other brokers), above its 21-week average of 50.2%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INTELLIGENT CROSS LLC (19.0%), UBS ATS (15.0%), IBKR ATS (9.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Notice of delisting or failure to meet listing rules
8-K on sec.govTop officer leaving
“On October 22, 2026, Nathen Fuentes resigned as Chief Financial Officer of the Company, effective immediately.”
8-K on sec.govSaid its annual or quarterly report would be late
NT 10-K on sec.govNotice of delisting or failure to meet listing rules
8-K/A on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.